Illumina, Inc.
Illumina, Inc. (NASDAQ: ILMN) is a global leader in sequencing and array-based solutions for genetic and genomic analysis. The company's website is www.illumina.com. Illumina serves customers across research institutions, academic centers, government laboratories, hospitals, pharmaceutical companies, biotechnology… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Illumina, Inc. does
In the company’s own words
Illumina, Inc. (NASDAQ: ILMN) is a global leader in sequencing and array-based solutions for genetic and genomic analysis. The company's website is www.illumina.com. Illumina serves customers across research institutions, academic centers, government laboratories, hospitals, pharmaceutical companies, biotechnology firms, commercial molecular diagnostic laboratories, and consumer genomics companies worldwide.
The company operates as a single reportable segment, Core Illumina, following the June 2024 spin-off of GRAIL into an independent publicly traded company. In 2025, sequencing revenue comprised 92 percent of total revenue, while array revenue represented 8 percent. Within sequencing, consumables accounted for 74 percent of total consolidated revenue, instruments for 11 percent, and services and other for 15 percent.
Illumina's core technology platforms include its proprietary sequencing by synthesis chemistry, known as XLEAP-SBS, which enables massively parallel DNA sequencing with high accuracy and throughput. The company's sequencing platforms can generate between 500 megabases and 16.0 terabases of genomic data per run depending on the instrument. The BeadArray technology platform supports array-based applications including SNP genotyping, copy number variation analysis, and methylation analysis. Illumina's informatics suite, BaseSpace, integrates with sequencing instruments to manage samples, process raw data, and enable analysis. The company also offers DRAGEN Bio-IT Platform for secondary analysis and Illumina Connected Analytics for cloud-based multi-omic data management.
As of December 28, 2025, Illumina employed approximately 8,600 full-time employees, 50 part-time employees, and 1,430 contingent workers globally. The company maintains principal facilities in San Diego, California; Singapore; Cambridge, United Kingdom; and the San Francisco Bay Area, with additional operations in Madison, Wisconsin; Eindhoven, Netherlands; China; and India. International shipments represented 48 percent of total consolidated revenue in 2025. The company holds an extensive intellectual property portfolio comprising 1,380 issued U.S. patents and 7,653 issued patents outside the United States as of December 28, 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- January
- CIK
- 1110803
- SIC
- 3826
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Illumina, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Illumina, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Illumina, Inc.’s bonds, as funds hold them
Funds report holding 4 issues of Illumina, Inc.’s debt, $565.88M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.76%, maturing 2026 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Illumina, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Illumina, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Illumina, Inc.'s last four quarterly filings that the numbers alone won't show?”